AMR & zoonotic risk
Zoonotic and Antimicrobial Resistance Risk
Two hidden health risks growing side by side. 'Antimicrobial resistance' means germs learning to survive the medicines we use against them, helped by heavy antibiotic use on farms. 'Zoonotic' means diseases that jump from animals to people, which happens more as forests are cut and the climate warms. Drug-resistant bacteria already directly kill more than a million people a year, and up to 80% of the antibiotics people and animals take leave the body unchanged.
Resistance rises; spillover risk grows with habitat disruption and warming.
Gradient 2.5 / 5 - weighed down most by the weakest enabler.
The average of these enablers is 2.6. The ramp runs at 2.5.
6 enablers have to mature together before this ramp steepens.
In the network
Also shaped by The Collapse of Shared Reality (1 shared enabler, 1 coupling) · The Inversion of the Population Pyramid (3 shared enablers) · The Optimisation of Everything (1 shared enabler) · The Rebuild of the Physical Base (5 shared enablers, 1 coupling)
Enablers
| Enabler | Family | Weight | Maturity | Role |
|---|---|---|---|---|
| Epistemic Trust | human | moderate | 2/5 | shared weakest link (with 1 other) |
| Synthetic Biology | technological | moderate | 2/5 | shared weakest link (with 1 other) |
| BioTech & Genomics | technological | moderate | 3/5 | - |
| Gene Editing | technological | moderate | 3/5 | - |
| Vaccine Platforms & Antimicrobials | technological | large | 3/5 | - |
- Epistemic Trustshared weakest link (with 1 other)2/5
- Synthetic Biologyshared weakest link (with 1 other)2/5
- BioTech & Genomicsmoderate · technological3/5
- Gene Editingmoderate · technological3/5
- Vaccine Platforms & Antimicrobialslarge · technological3/5
The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull. Everything above 2 is strength this ramp can use only in part until the weakest link moves.
What this pushes on, and what pushes on it
Pushed on by
- Biodiversity LossamplifiesHabitat conversion increases human-wildlife contact at the interface where spillover occurs.
- Food System TransformationamplifiesIntensifying livestock production drives antibiotic use on farms, which accelerates resistance.
- Pollution and Waste BurdenamplifiesPharmaceutical and agricultural residues in the environment select for resistance.
Bound by
Agricultural antibiotic practice and pharma investment
The economics of antibiotic development (low return) and the politics of agricultural reform (high resistance).
Momentum. Biological and compounding. Resistance accumulates as long as antibiotics are used, and use is rising fastest in agriculture.
The four clocks
Four systems absorb this at four speeds. The distance between them is the adaptation gap.
Individuals
monthsFast to demand an antibiotic, and the demand is part of the mechanism.
Companies
yearsThe pharmaceutical industry has largely exited, rationally, because the best public-health outcome is the worst commercial one.
Governments
decadesAdvance purchase commitments and subscription models exist and are far below the scale the curves imply.
The biosphere
not ours to setHabitat disruption and warming raise spillover risk on their own schedule, independent of any health system.
Impacts by domain
Social & demographic
Antibiotic resistance is already a leading cause of death, not a future threat: drug-resistant bacteria directly caused 1.14 million deaths in 2021 and were associated with 4.71 million in all worldwide (GBD 2021 Antimicrobial Resistance Collaborators, The Lancet, September 2024).
Environmental
Antibiotics do not stay in the body: up to 80% of the antibiotics given to people and animals are excreted unmetabolised in urine and faeces (UN Environment, Frontiers Report 2017, as reported by CIDRAP).
Economic
Resistant infections are an expensive complication hospitals didn't budget for: treating multidrug-resistant infections cost US hospitals $4.6 billion in 2017, with the worst cases running to over $74,000 per patient (Nelson et al., Clinical Infectious Diseases, January 2021).
Geopolitical
Contested: most countries have a plan on paper and no money to run it: 93% of 177 countries surveyed had a national action plan on antimicrobial resistance in 2023, but only 40% had secured funding to actually operate it (Quadripartite TrACSS, May 2024).
What would prove this wrong
Resistance rates falling in a major economy following an agricultural antibiotic restriction, or a novel antibiotic class reaching market under a pull incentive that makes the economics work.
Talin, B. (2026). Zoonotic and Antimicrobial Resistance Risk. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/m/zoonotic-and-antimicrobial-resistance-risk/